The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13 554 patients in England

Abstract

Mirtazpine is the first noradrenaline and serotonin specific antidepressant. We monitored the safety of mirtazapine as reported in primary practice in England.The exposure data were provided by monitoring the dispensed prescriptions issued between September 1997 and February 1999. Questionnaires sent to GPs provided outcome data. Drowsiness/sedation and malaise/lassitude were the most frequent ADRs (116, 71 respectively) and had the highest incidence density (per 1000 patient-months) in the first month of treatment (58.1, 27.8 respectively). Agitation (73), aggression (70), rash (20), hallucinations (13) and abnormal dreams (31 were unlabelled AES while abnormal liver function tests (12), syncope (8), abnormal behaviour (4) and visual disturbance (3) were labelled AES possibly due to mirtazapine use. Serious suspected ADRs reported were facial oedema (5), allergy (3), bone marrow toxicity (2) and myelodysplasia (1).

Keywords

agitation aggression drowsiness/sedation mirtazapine prescription event monitoring post-marketing surveillance safety

Get full access to this article

View all access options for this article.

References

CIOMS/WHO (1993) International ethical guidelines for biomedical research involving human subjects. Geneva, Switzerland: Council for International Organisations of Medical Sciences/ World Health Organization

Davidson J R , Meltzer-Brody S E (1999) The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 60(Suppl. 7): 1–10

De Boer T (1996) The pharmacological profile of mirtazapine. J Clin Psychiatry 57(Suppl 4): 19–25

Fava M (2000) Weight gain and antidepressants. J Clin Psychiatry 61(Suppl 11): 37–41

Fawcett J , Barkin R L (1998) Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients in major depression. J Affect Disord 51: 267–285

Freemantle S N , Pearce G L , Wilton L V , Mann R D (1996) The incidence of the most commonly reported events with 40 newly marketed drugs – a study by prescription-event monitoring. Pharmacoepidemiol Drug Safety 6(Suppl 1): 1–8

Goldberg D , Tantam D (1991) The public health impact of mental disorders. In Holland W W , Detels R , Knox G (eds), Oxford text book of public health, vol. 3, application in public health, 2nd edn, pp. 268–269. Oxford: Oxford University Press

Heeley E , Riley J , Layton D , Wilton L V , Shakir S A W (2001) Prescription event monitoring and reporting of adverse drug reactions. Lancet 358: 1872–1873

Mackay F J , Dunn N R , Wilton L V , Pearce G L , Freemantle S N , Mann R D (1997) A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Safety 6: 235–246

10.

McAvoy B R , Kramer E F S (1996) General practice postal surveys: a questionnaire too far? BMJ 313: 732–733

11.

Montgomery S A (1995) Safety of mirtazapine: a review. Int J Clin Psychopharmacol 10(Suppl 4): 37–45

12.

Organon Laboratories (1997) Mirtazapine summary of product characteristics. The Netherlands: Organon Laboratories

13.

Royal College of Physicians of London (1996) Guidelines on the practice of ethical committees in medical research involving human subjects. London: Royal College of Physicians of London

14.

Templeton L , Deeham A , Taylor C , Drummond C , Strang J (1997) Surveying general practitioners: does a low response rate matter? Br J Gen Pract 47: 91–94

15.

Tylee A , Priest R , Roberts A (1966) Depression in general practice. London: Martin Dunitz

16.

Ward H E (1997) The newer antidepressants. J Int Med 18: 65–70